U.S. stock market mid-session update: Akanda plummets nearly 18%, trading volume surges, market volatility draws attention

U.S. Stock Market Midday Update Akanda, down 17.95%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Eli Lilly up 0.51%, with increased trading volume. Based on recent news, On January 12, Eli Lilly announced plans to acquire the French biotechnology company Abivax for approximately $17.5 billion, which, if successful, will expand its influence in Europe and acquire key R&D assets. This news drove Abivax's stock price up by 6.1%. On January 12, Eli Lilly and NVIDIA announced a joint investment of $1 billion over the next five years to establish an AI pharmaceutical lab in Silicon Valley, aimed at accelerating drug development. This move demonstrates the potential of AI technology in the medical field. On January 12, Eli Lilly's small molecule GLP-1R agonist, orforglipron, was submitted for listing in China, which is expected to further expand its market share. The application prospects of AI technology in the medical field are broad. Johnson & Johnson up 1.50%. Based on recent news, On January 13, Johnson & Johnson's CEO stated that the company will focus on early-stage deals by 2026 and has sufficient financial strength to seize opportunities. This news boosted market confidence in the company's future growth, driving the stock price up. On January 13, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's Rybrevant Faspro, the first and only subcutaneous therapy for epidermal growth factor receptor mutation non-small cell lung cancer. This approval further solidified Johnson & Johnson's leading position in oncology treatment and boosted investor sentiment. On January 13, Johnson & Johnson reached an agreement with the Trump administration to lower drug prices for U.S. customers in exchange for tariff exemptions. This move is seen as an aggressive strategy in the U.S. market, further driving the stock price up. The pharmaceutical industry is performing strongly, with favorable policies. Novo Nordisk up 0.51%. Based on recent key news: On January 13, Novo Nordisk's CEO stated that communication with the Trump administration is smooth, enhancing market confidence in the company's policy support, driving the stock price up. On January 13, Novo Nordisk's Vice President of Product Strategy pointed out that the market size for oral weight loss drugs exceeds expectations, and the market is optimistic about the company's product prospects, benefiting the stock price. On January 13, Novo Nordisk's CEO emphasized that the priority for capital allocation remains unchanged, planning small-scale acquisitions, and investors expect the company to continue creating value, leading to a rise in stock price. The weight loss drug market is growing rapidly, with significant policy support. Stocks with High Market Capitalization in the Industry AstraZeneca up 0.23%. Based on recent key news: On January 13, the UK pharmaceutical industry faces structural challenges affecting companies like AstraZeneca. The regulatory adjustments post-Brexit and the challenges of the National Health Service are putting pressure on pharmaceutical innovation, leading to stock price volatility for AstraZeneca On January 14th, the application of artificial intelligence tools in drug trials improved clinical success rates and reduced associated costs. This technological advancement may have a positive impact on AstraZeneca's R&D efficiency. On January 12th, the impact of climate change on supply chains is seen as a competitive advantage. AstraZeneca may benefit from supply chain stability, enhancing market competitiveness. The pharmaceutical industry faces structural challenges and focuses on innovation